Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Net Income: 2022-2025

Historic Net Income for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to -$47.2 million.

  • Axsome Therapeutics' Net Income rose 26.89% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 26.20%. This contributed to the annual value of -$287.2 million for FY2024, which is 20.05% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Net Income is -$47.2 million, which was up 1.47% from -$47.9 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Net Income ranged from a high of -$11.2 million in Q1 2023 and a low of -$98.6 million during Q4 2023.
  • In the last 3 years, Axsome Therapeutics' Net Income had a median value of -$64.6 million in 2024 and averaged -$61.9 million.
  • Per our database at Business Quant, Axsome Therapeutics' Net Income surged by 71.64% in 2023 and then tumbled by 508.27% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Net Income (Quarterly) stood at -$61.2 million in 2022, then crashed by 61.06% to -$98.6 million in 2023, then rose by 24.05% to -$74.9 million in 2024, then increased by 26.89% to -$47.2 million in 2025.
  • Its Net Income was -$47.2 million in Q3 2025, compared to -$47.9 million in Q2 2025 and -$59.4 million in Q1 2025.